11 posts in this category
The FDA warned Novo Nordisk for not reporting deaths and serious side effects tied to its GLP-1 medications. Here is what happened.
Hearing new GLP-1 names? Learn why language changed, what stayed the same, and how to tell if your medication actually changed.
Learn how to identify fake Ozempic, check packaging and lot numbers, and avoid online GLP-1 scams. Simple safety tips for families.
What does GLP-1/GIP mean? Learn how dual GIP/GLP-1 medications differ from GLP-1 drugs and why terminology is changing.
Research GLP-1 peptides are often sold online outside the medical system. Learn what they are, why they’re risky, and how to spot grey-market products.
FDA review finds no increased suicide risk with GLP-1 medications and is asking for related label warnings to be removed.
See how states, Medicare, Medicaid, and employer plans are handling GLP-1 coverage changes in 2026 and what it means for your insurance.
FDA: “many of the adverse events reported for compounded versions appear to be consistent with adverse events for the FDA‑approved products.”
We’ve all been hearing about the shortage of tirzepatide or semaglutide, but what is a shortage? How does it impact compounding?
The FDA has ended the shortage for tirzepatide, essential copy compounding ends on Feb 18 and March 19
OFA vs FDA Case Join report Nov 21
